Elmind Capital LP Acquires New Stake in Alumis Inc. $ALMS

Elmind Capital LP acquired a new stake in Alumis Inc. (NASDAQ:ALMS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 130,000 shares of the company's stock, valued at approximately $3,658,200. Alumis accounts for approximately 0.0% of Elmind Capital LP's holdings, making the stock its 24th largest position. Elmind Capital LP owned about 0.10% of Alumis as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock worth $26,000 after buying an additional 4,894 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock valued at $35,000 after purchasing an additional 7,467 shares during the last quarter. KBC Group NV acquired a new position in Alumis in the 1st quarter worth about $42,000. Strs Ohio grew its position in Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company's stock worth $44,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company's stock worth $46,000 after purchasing an additional 979 shares in the last quarter.

Insiders Place Their Bets

In other Alumis news, CFO John R. Schroer sold 3,282 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $86,546.34. Following the sale, the chief financial officer directly owned 24,718 shares of the company's stock, valued at approximately $651,813.66. This represents a 11.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David M. Goldstein sold 2,596 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $68,456.52. Following the transaction, the insider owned 30,970 shares of the company's stock, valued at $816,678.90. This trade represents a 7.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 19,953 shares of company stock valued at $534,311 in the last three months. 33.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ALMS shares. Guggenheim lifted their price objective on shares of Alumis from $32.00 to $34.00 and gave the company a "buy" rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alumis in a report on Tuesday, July 7th. Wall Street Zen raised Alumis from a "strong sell" rating to a "hold" rating in a research report on Sunday, August 23rd. Citigroup restated a "neutral" rating on shares of Alumis in a report on Monday, August 17th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price objective on shares of Alumis in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.30.

Alumis Stock Down 3.1%

Shares of NASDAQ ALMS traded down $0.72 during mid-day trading on Friday, reaching $22.49. 400,135 shares of the company were exchanged, compared to its average volume of 1,909,739. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35. The stock has a market capitalization of $2.91 billion, a P/E ratio of -5.83 and a beta of -0.69. The company's 50-day simple moving average is $26.57 and its 200-day simple moving average is $25.11.

Alumis (NASDAQ:ALMS - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. As a group, equities research analysts expect that Alumis Inc. will post -2.95 EPS for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source